Scholarlink

Background <p>Surprisingly few medicines are available to prevent or manage pre-eclampsia, all of which are repurposed from non-pregnant populations and conditions. Analyses of clinical research and development pipelines for pre-eclampsia medicines have identified high-potential candidates; however, the preclinical pipeline has not been interrogated. To address this gap, we developed an approach to analyse and rank preclinical candidates and applied it to the preclinical pipeline for pre‑eclampsia and eclampsia.</p> Methods <p>We analysed and ranked the potential of 83 preclinical candidates for pre-eclampsia and eclampsia identified in the Maternal Health Pipeline spanning 2000 to 2025. Candidates were assessed across three domains – quality of preclinical evidence, product development stage and implementability. Each question in the prioritisation matrix was assigned a numerical value based on importance. The sum of these values was used to rank the potential of each candidate for future research.</p> Results <p>There is a total of 106 candidates in the preclinical pipeline. Twenty-three candidates are excluded from our analysis. Among the 83 candidates analysed, 11 high-potential candidates are identified, and the remaining candidates are ranked as medium (63 candidates) and low potential (nine candidates). Of the candidates analysed, 49.4% are new chemical or biological entities, 37 different binding targets are identified and the proposed mechanism of action for 32 candidates is a reduction in angiogenic factor sFlt-1.</p> Conclusions <p>High potential candidates should be prioritised for further development, but progress is restricted by current mechanisms of action and animal models. Increased investment is essential to advance pre-eclampsia therapies into clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The global preclinical research and development landscape for pre-eclampsia and eclampsia therapies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月14日

查看全文
  • Jessica Postregna,
  • Kate Mills,
  • Fiona Bruinsma,
  • Maya Goldstein,
  • Andrew Tuttle,
  • Lindsay Keir,
  • Cecile Ventola,
  • A. Metin Gülmezoglu,
  • Anne Ammerdorffer,
  • Joshua P. Vogel,
  • Annie R. A. McDougall

摘要

Background

Surprisingly few medicines are available to prevent or manage pre-eclampsia, all of which are repurposed from non-pregnant populations and conditions. Analyses of clinical research and development pipelines for pre-eclampsia medicines have identified high-potential candidates; however, the preclinical pipeline has not been interrogated. To address this gap, we developed an approach to analyse and rank preclinical candidates and applied it to the preclinical pipeline for pre‑eclampsia and eclampsia.

Methods

We analysed and ranked the potential of 83 preclinical candidates for pre-eclampsia and eclampsia identified in the Maternal Health Pipeline spanning 2000 to 2025. Candidates were assessed across three domains – quality of preclinical evidence, product development stage and implementability. Each question in the prioritisation matrix was assigned a numerical value based on importance. The sum of these values was used to rank the potential of each candidate for future research.

Results

There is a total of 106 candidates in the preclinical pipeline. Twenty-three candidates are excluded from our analysis. Among the 83 candidates analysed, 11 high-potential candidates are identified, and the remaining candidates are ranked as medium (63 candidates) and low potential (nine candidates). Of the candidates analysed, 49.4% are new chemical or biological entities, 37 different binding targets are identified and the proposed mechanism of action for 32 candidates is a reduction in angiogenic factor sFlt-1.

Conclusions

High potential candidates should be prioritised for further development, but progress is restricted by current mechanisms of action and animal models. Increased investment is essential to advance pre-eclampsia therapies into clinical trials.